Atlas Trials

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Clinical trial NCT05202782 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05202782
Sponsor
Northwestern University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedLarge B-Cell Lymphoma With IRF4 RearrangementPrimary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent Intravascular Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin Lymphoma
Start date
2022-03-21
Primary completion
2026-10-09
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.